Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000813391 | SCV000953750 | pathogenic | not provided | 2023-09-12 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with MSH3-related conditions. This sequence change creates a premature translational stop signal (p.Thr959Serfs*17) in the MSH3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH3 are known to be pathogenic (PMID: 27476653, 37402566). This variant is not present in population databases (gnomAD no frequency). ClinVar contains an entry for this variant (Variation ID: 656877). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002440772 | SCV002745940 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-03-22 | criteria provided, single submitter | clinical testing | The c.2876_2877delCA pathogenic mutation, located in coding exon 21 of the MSH3 gene, results from a deletion of two nucleotides at nucleotide positions 2876 to 2877, causing a translational frameshift with a predicted alternate stop codon (p.T959Sfs*17). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003458543 | SCV004189099 | pathogenic | Familial adenomatous polyposis 4 | 2023-08-31 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |